FibroBiologics Inc. FBLG
1.39
0.03
2.21%
as of 25 Sep
- Market cap
- $9.1M
- P/E
- 0.0×
Follow FBLG
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
2.64 | 1.59 | 3.61 | 0.78 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.91 | 0.31 | 2.08 | 0.06 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 52.30% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 36.58 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.87 | 0.98 | 0.69 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.03) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.52) | (1.16) | (1.42) | (1.85) | |
Cash per Share |
0.56 | 0.39 | 2.19 | 2.26 | |
Shareholders Equity per Share |
0.74 | 0.69 | 2.76 | 0.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.74 | 0.69 | 2.76 | 0.06 | |
Free Cash Flow |
(3.29) | (4.36) | (3.16) | (3.98) | |
Working Capital |
3.64 | 1.08 | 4.59 | (1.48) | |
Capital Expenditures |
— | — | 0.00 | (0.01) | |
Net Current Asset Value |
2.56 | (0.43) | 2.89 | (3.38) | |
| Other line items | |||||
Quick Ratio |
1.59 | 0.81 | 2.78 | 0.72 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.52) | (1.16) | (1.42) | (1.84) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.81 | 1.13 | 1.82 | 1.12 | |
Average Assets |
10.92 | 8.68 | 13.03 | 9.61 | |
Average Common Equity |
2.75 | 2.48 | 4.45 | 1.43 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates